Bristol Myers Squibb's Presentations at ASH 2024 Reinforce ...

AstraZeneca showcases strength of haematology portfolio and ...

AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 · First results from AMPLIFY trial will reinforce Calquence as ...

Bristol Myers Squibb's First Disclosures and New Data at ASH 2023 ...

Bristol Myers Squibb today announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65 th ...

Abstract Submission | ASCO Annual Meeting

The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ... Bristol Myers Squibb. Sponsorship Donors (Silver). Body. HELSINN. Annual Meeting ...

Studies Show Improved Sickle Cell Disease Outcomes Worldwide

(San Diego, December 1, 2018) — Today at the 60th American Society of Hematology (ASH) ... Bristol-Myers Squibb donated the hydroxyurea capsules.

Corporate news details - Bristol Myers Squibb - Press Releases

... Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63 rd American Society of Hematology (ASH) ...

Research & Development Day - Bristol Myers Squibb

ASH 2022 [Presentation #3314]. Grade ≥3 n=31. CRS. 0. iiNT. 3.2 ... Data expected later this year & launch anticipated in 2024/2025. U.S. ...

Corporate news details - Bristol Myers Squibb - Press Releases

These data are being presented in an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting, from December 9-12 ...

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti ...

“The breadth of data presented at ASH from across our studies underscores our commitment to the continued innovation of cell therapies for ...

Q4 2023 Results - Bristol Myers Squibb

This presentation includes certain non-generally accepted accounting principles (“GAAP”) financial measures that we use to describe the ...

Corporate news details - Bristol Myers Squibb

Phase 3 TRANSFORM study shows Breyanzi significantlyimproved event-free survival (EFS) vs. chemotherapy plus autologous stem cell transplant.

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA ...

Q3 2023 Results - Bristol Myers Squibb

This presentation contains statements about Bristol-Myers Squibb ... • Ph2 expected to initiate 1H 2024; Fast Track Designation granted.

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial ...

Expects significant free cash flow generation of $45-$50 billion dollars from 2022-2024. This financial guidance excludes the impact of any ...